Blueprint Medicines Corp (BPMC)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Kathryn Haviland
Employees:
640
45 SIDNEY STREET, CAMBRIDGE, MA 02139
617-374-7580

Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.

Data derived from most recent annual or quarterly report
Market Cap 3.019 Billion Shares Outstanding60.467 Million Avg 30-day Volume 450.013 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.68
Price to Revenue16.9519 Debt to Equity2.0441 EBITDA-508.18 Million
Price to Book Value12.2926 Operating Margin-233.2575 Enterprise Value3.624 Billion
Current Ratio4.8 EPS Growth0.225 Quick Ratio4.502
1 Yr BETA 0.9948 52-week High/Low 68.63 / 37.82 Profit Margin-245.6229
Operating Cash Flow Growth-39.9341 Free Cash Flow to Firm (FCFF) TTM -507.087 Million Free Cash Flow to Equity (FCFE) TTM-378.733 Million
Altman Z-Score-0.4284
Earnings Report2023-10-31
View SEC Filings from BPMC instead.

View recent insider trading info

Blueprint Medicines Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding BPMC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BPMC

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-28 by ALBERS JEFFREY W.
  • 4: filed on 2023-06-23 by ALBERS JEFFREY W.
  • 4: filed on 2023-06-23 by TSAI JOHN
  • 4: filed on 2023-06-23 by DABLE HABIB J
  • 4: filed on 2023-06-23 by COATS LONNEL
  • 4: filed on 2023-06-23 by LYDON NICHOLAS
  • 4: filed on 2023-06-07 by CARTER PERCY H.
  • 4: filed on 2023-06-07 by HEWES L. BECKER
  • 4: filed on 2023-01-09 by TSAI JOHN
  • 3: filed on 2023-01-09 by TSAI JOHN

    • Events (8k)

  • 8-K: filed on 2023-08-25:
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-30:
    Item 8.01: Other Events
  • 8-K: filed on 2023-06-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-23:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-08-24:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    25 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    25 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ALBERS JEFFREY W.

    • Director
    		 176,050 2023-08-24 4

    BORISY ALEXIS

    • Director
    		 71,918 2023-06-21 1

    SEELY LYNN

    • Director
    		 11,012 2023-06-21 1

    BECKMAN DANIELLA

    • Director
    		 8,600 2023-06-21 1

    GOLDBERG MARK ALAN

    • Director
    		 16,012 2023-06-21 1

    COATS LONNEL

    • Director
    		 11,012 2023-06-21 1

    LYDON NICHOLAS

    • Director
    		 55,784 2023-06-21 1

    DABLE HABIB J

    • Director
    		 6,500 2023-06-21 1

    TSAI JOHN

    • Director
    		 6,500 2023-06-21 3

    HEWES L. BECKER CHIEF MEDICAL OFFICER

    • Officer
    		 36,878 2023-06-05 3

    CARTER PERCY H. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 38,117 2023-06-05 3

    LANDSITTEL MICHAEL CHIEF FINANCIAL OFFICER

    • Officer
    		 48,523 2023-03-06 2

    HAVILAND KATE CHIEF EXECUTIVE OFFICER

    • Officer
    		 125,641 2023-03-06 3

    MCCAIN TRACEY L EVP AND CHIEF LEGAL OFFICER

    • Officer
    		 52,666 2023-03-06 2

    MURRAY CHRISTOPHER K. CHIEF TECHNICAL OPERATIONS

    • Officer
    		 25,695 2023-03-06 2

    ROSSI CHRISTINA CHIEF OPERATING OFFICER

    • Officer
    		 55,376 2023-03-06 3

    HURLEY ARIEL PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 14,175 2023-03-06 2

    DURSO-BUMPUS DEBRA CHIEF PEOPLE OFFICER

    • Officer
    		 50,178 2023-03-06 2

    NAMOUNI FOUAD PRESIDENT, R & D

    • Officer
    		 65,849 2023-03-06 3

    LEE PHILINA CHIEF COMMERCIAL OFFICER

    • Officer
    		 31,178 2023-03-06 2

    DEMETRI GEORGE

    • Director
    		 13,712 2022-06-21 0

    TANGO THERAPEUTICS, INC.

    • Director
    		 10,400 2021-12-08 0

    ROWLAND CHARLES A JR

    • Director
    		 10,312 2021-06-02 0

    DORSCH MARION CHIEF SCIENTIFIC OFFICER

    • Officer
    		 55,672 2021-02-22 0

    BORAL ANTHONY L. CHIEF MEDICAL OFFICER

    • Officer
    		 28,147 2020-12-14 0

    LYNCH DANIEL

    • Director
    		 127,904 2020-06-24 0

    LEVIN MARK J

    • 10% Owner
    		 3,564,997 2017-03-16 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    LEVIN MARK J

    STARR KEVIN P

    TEPPER ROBERT I

    • 10% Owner
    		 3,770,987 2017-02-27 0

    STARR KEVIN P

    • 10% Owner
    		 5,453,753 2016-12-19 0

    LENGAUER CHRISTOPH CHIEF SCIENTIFIC OFFICER

    • Officer
    		 56,657 2016-04-13 0

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2015-11-25 0

    KUVALANKA KYLE D. CHIEF BUSINESS OFFICER

    • Officer
    		 33,670 2015-04-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ALBERS JEFFREY W. - Director

    		2023-08-28 18:23:36 -0400 2023-08-25 M 10,000 $1.87 a 186,050 direct yes 0.9212 2.4565 3.6643 4 0.0 1

    ALBERS JEFFREY W. - Director

    		2023-08-28 18:23:36 -0400 2023-08-25 S 10,000 $50.16 d 176,050 direct yes 0.9212 2.4565 3.6643 4 0.0 1

    ALBERS JEFFREY W. - Director

    		2023-08-28 18:23:36 -0400 2023-08-25 M 10,000 d 70,073 direct yes

    ALBERS JEFFREY W. - Director

    		2023-08-28 18:23:36 -0400 2023-08-24 M 15,000 $1.87 a 191,050 direct yes 0.9212 2.4565 3.6643 4 0.0 1

    ALBERS JEFFREY W. - Director

    		2023-08-28 18:23:36 -0400 2023-08-24 S 15,000 $49.57 d 176,050 direct yes 0.9212 2.4565 3.6643 4 0.0 1

    ALBERS JEFFREY W. - Director

    		2023-08-28 18:23:36 -0400 2023-08-24 M 15,000 d 80,073 direct yes

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 22:15:05 UTC 5.0637 0.2563 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 21:45:03 UTC 5.0637 0.2563 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 21:15:04 UTC 5.0637 0.2563 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 20:45:04 UTC 5.0637 0.2563 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 20:15:05 UTC 5.0614 0.2586 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 19:45:03 UTC 5.0614 0.2586 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 19:15:04 UTC 5.0614 0.2586 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 18:45:04 UTC 5.0538 0.2662 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 18:15:04 UTC 5.0538 0.2662 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 17:45:03 UTC 0.0 0.0 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 17:15:03 UTC 0.0 0.0 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 16:45:04 UTC 5.0518 0.2682 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 16:15:05 UTC 5.0518 0.2682 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 15:45:04 UTC 5.0504 0.2696 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 15:15:03 UTC 5.0504 0.2696 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 14:45:03 UTC 5.0255 0.2945 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 14:15:03 UTC 5.0255 0.2945 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 13:45:03 UTC 5.0633 0.2567 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 13:15:05 UTC 5.0633 0.2567 1200000
    BLUEPRINT MEDICINES CORP BPMC 2023-09-27 12:45:05 UTC 5.0633 0.2567 1200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Advisors Series Trust- Pzena Long/Short Value Fund BPMC -1323.0 shares, $-86180.22 2020-05-31 N-PORT
    Trust for Professional Managers- Convergence Market Neutral Fund BPMC -897.0 shares, $-69454.71 2020-08-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund BPMC -37.0 shares, $-2163.76 2020-03-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund BPMC -25.0 shares, $-2317.5 2020-09-30 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund BPMC -679.0 shares, $-65319.8 2021-11-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund BPMC -228.0 shares, $-9988.68 2022-12-30 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund BPMC -432.0 shares, $-22053.6 2023-04-30 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity ETF BPMC -1486.0 shares, $-83988.72 2023-05-31 N-PORT
    AGF Investments Trust- AGF U.S. Market Neutral Anti-Beta Fund BPMC -23076.0 shares, $-1458403.2 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments